Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers-Reference-Cited by-同舟云学术

Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers

Published:2019-07-17 Issue:7 Volume:14 Page:e0219060
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Dusselier Matthieu^ORCID,Deluche Elise,Delacourt Nellie,Ballouhey Julia,Egenod Thomas,Melloni Boris,Vergnenègre Charlotte,Veillon Rémi,Vergnenègre Alain

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference33 articles.

1. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer;J Brahmer;N Engl J Med,2015

2. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer;H Borghaei;N Engl J Med,2015

3. How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances;JL Messerschmidt;The Oncologist,2016

4. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway;KC Ohaegbulam;Trends Mol Med,2015

5. PD-1 blockade induces responses by inhibiting adaptive immune resistance;PC Tumeh;Nature,2014

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulation: A new approach to cancer cachexia, potentially suitable for aging;Molecular Aspects of Medicine;2024-12

2. Monocytes-to-lymphocytes ratio increases the prognostic value of circulating tumor cells in non-small cell lung cancer: a prospective study;Translational Cancer Research;2024-07

3. The Predictive Biomarkers of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer;Advances in Clinical Medicine;2024

4. Neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as potential predictive markers of treatment response in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis;Frontiers in Oncology;2023-10-26

5. Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors;Frontiers in Immunology;2023-05-22